← Human Trials & Peer-Reviewed Studies
Effect of vasopressin and methylprednisolone vs. placebo on long-term outcomes in patients with in-hospital cardiac arrest a randomized clinical trial
Plain-language guide to PMID 35490936 (2022): double-blind randomized controlled trial study of Vasopressin.
Key Facts
- PMID
- 35490936
- Journal
- Resuscitation
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Granfeldt A et al. (31 authors)
- DOI
- 10.1016/j.resuscitation.2022.04.017
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vasopressin in this randomized controlled trial publication.
The primary results from the Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial have previously been reported.
The objective of the current manuscript is to report long-term outcomes.
Who Took Part
By PubMed's age tags, the people studied were teenagers and adults.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.
As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.
Running at several centres spread the Vasopressin study over different clinics and patient groups.
The VAM-IHCA trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted at ten hospitals in Denmark.
This manuscript report outcomes at 6 months and 1 year including survival, survival with favorable neurological outcome, and health-related quality of life.
What Was Measured
Topics PubMed links to this paper include Cardiopulmonary Resuscitation, Epinephrine, Heart Arrest, Hospitals, Methylprednisolone, Quality of Life and Vasopressins.
The authors tagged it with the keywords In-hospital cardiac arrest, Long-term and Outcomes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vasopressin.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Resuscitation), a journal based in Ireland.
More context: the Vasopressin compound page, all human trials.
Our Notes on the Compound
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.